Background Combined inhibition of vascular, platelet-derived, and epidermal growth factor
receptor (EGFR) pathways may overcome refractoriness to single agents in platinum …

Purpose Sunitinib plus erlotinib may enhance antitumor activity compared with either agent
alone in non–small-cell lung cancer (NSCLC), based on the importance of the signaling …

Background: This randomized, double-blind, multicenter study evaluated sunitinib plus
erlotinib versus placebo plus erlotinib. Subjects with advanced non–small-cell lung cancer …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (egfr-tkis) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …